Content overview
Amorphous solid dispersions (ASDs) have emerged as a widely used strategy to enhance the solubility and bioavailability of poorly water-soluble drugs, solving a key challenge in pharmaceutical development. By dispersing the active pharmaceutical ingredient (API) within an excipient matrix in an amorphous state, ASDs eliminate the need for energy to break the drug’s crystal lattice, facilitating improved dissolution and absorption.
A major challenge with amorphous materials is their inherent instability, as they tend to recrystallize over time, leading to a loss of their enhanced solubility and bioavailability. Excipients, particularly polymers, play a crucial role in the formation and stabilization of amorphous solid dispersions (ASDs). Polymers act as carriers that inhibit drug recrystallization, enhance solubility, and improve the overall stability of the formulation. The selection and characterization of polymers, including their solubility, stability, and drug interactions, are key to optimizing formulations for enhanced bioavailability and long-term stability.
This application note presents three case studies demonstrating the role of Crystal16 in ASD research, showcasing its effectiveness in screening and optimizing drug-excipient combinations to enhance solubility and stability.
The case studies are:
- Enhancing ASD performance through Surface Engineering
- The Effect of Inorganic Salt on Amorphous Solid Dispersion
- Amorphous Solid Dispersions Produced from Various Solvent Systems
